Scholarlink

<p>Mechanisms linking CD33 variants to Alzheimer Disease (AD) are poorly defined. Here, we combine structural, cellular, and genetic analyses to delineate how the CD33<sup>M</sup> splice isoform, upregulated in carriers of CD33 risk alleles, modulates microglial function. We show that CD33<sup>M</sup> ectodomain dimerizes, enabling binding of large multi-sialylated molecules. We demonstrate that another AD risk protein - clusterin (CLU) ± Aβ oligomers (but not ApoE) binds with nanomolar avidity to CD33<sup>M</sup>, but not CD33<sup>m</sup>. We show that in human monocytes CD33<sup>M</sup>:CLU binding induces CD33<sup>M</sup> ITIM phosphorylation, recruits SHP-1, suppresses Aβ phagocytosis, and impairs clearance of amyloid plaques. We identify a soluble CD33<sup>M</sup> ectodomain fragment (sCD33<sup>M</sup>) - absent from CD33<sup>m</sup>-expressing cells - which could contribute to the role of CD33<sup>M</sup> in AD. Genetic analyses confirm that CD33:CLU interaction modulates amyloid burden, cognition, and disease risk. These findings define a mechanistic CLU:Aβ:CD33<sup>M</sup> axis, highlighting CD33<sup>M</sup> dimerization and ligand-binding sites as potential therapeutic targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月17日

查看全文
  • Roger B. Dodd,
  • Masahiro Enomoto,
  • Ye Zhou,
  • Kanayo Satoh,
  • Yalun Zhang,
  • Fusheng Chen,
  • Beatrice Acheson,
  • Deniz Ghaffari,
  • Elizabeth Sayn-Wittgenstein,
  • Jamie J. Manning,
  • George V. Dukas,
  • Ronak Patel,
  • Alondra Schweizer Burguete,
  • Mason J. Kralovec,
  • Mamunur Rashid,
  • Jennifer L. Hall,
  • Kirstin A. Tamucci,
  • Zena Chatila,
  • Minghua Liu,
  • Annie J. Lee,
  • Badri N. Vardarajan,
  • Mariko F. Taga,
  • Sirkku Pollari,
  • Alon Rabinovitch,
  • Cory D. Rillahan,
  • Andrey A. Bobkov,
  • Eduard Sergienko,
  • William Meadows,
  • Seema Qamar,
  • Suzanne J. Randle,
  • Christopher M. Johnson,
  • Jean Sevalle,
  • Jennifer Griffin,
  • Christopher Bohm,
  • Mitsuhiko Ikura,
  • Xunde Xian,
  • Joachim Herz,
  • Megan A. Kelly,
  • Jennifer West,
  • Sandeep Satapathy,
  • Mark R. Wilson,
  • Jonathan A. Javitch,
  • Paul E. Fraser,
  • David A. Bennett,
  • Philip L. De Jager,
  • Zvi Fishelson,
  • Dan Frenkel,
  • Wesley B. Asher,
  • Elizabeth M. Bradshaw,
  • Peter St George-Hyslop

摘要

Mechanisms linking CD33 variants to Alzheimer Disease (AD) are poorly defined. Here, we combine structural, cellular, and genetic analyses to delineate how the CD33M splice isoform, upregulated in carriers of CD33 risk alleles, modulates microglial function. We show that CD33M ectodomain dimerizes, enabling binding of large multi-sialylated molecules. We demonstrate that another AD risk protein - clusterin (CLU) ± Aβ oligomers (but not ApoE) binds with nanomolar avidity to CD33M, but not CD33m. We show that in human monocytes CD33M:CLU binding induces CD33M ITIM phosphorylation, recruits SHP-1, suppresses Aβ phagocytosis, and impairs clearance of amyloid plaques. We identify a soluble CD33M ectodomain fragment (sCD33M) - absent from CD33m-expressing cells - which could contribute to the role of CD33M in AD. Genetic analyses confirm that CD33:CLU interaction modulates amyloid burden, cognition, and disease risk. These findings define a mechanistic CLU:Aβ:CD33M axis, highlighting CD33M dimerization and ligand-binding sites as potential therapeutic targets.